{"id":"W4236866569","doi":"10.1200/jco.2012.30.15_suppl.lba3500","title":"Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Erlotinib; Colorectal cancer; Oncology; Internal medicine; Chemotherapy; Cancer; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009017019,0.0004979821,0.001327028,0.000276637,0.000174236,0.0007917039,0.000529235,0.0005952167,0.002307214],"category_scores_gemma":[0.001154195,0.0002491301,0.000653378,0.0004396549,0.000370892,0.0008040281,0.0002903903,0.002220316,0.0005637293],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006390194,"about_ca_system_score_gemma":0.0007438081,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001308395,"about_ca_topic_score_gemma":0.005684519,"domain_scores_codex":[0.9997734,0.0001029936,0.00001392204,0.00003156306,0.00003361921,0.00004443733],"domain_scores_gemma":[0.9996586,0.00007569342,0.00008633536,0.00002610213,0.00001703678,0.0001363148],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6362365,0.008251484,0.005479943,0.001655046,0.002140904,0.0001708905,0.0001739867,0.00187514,0.0132098,0.0005430543,0.01474523,0.315518],"study_design_scores_gemma":[0.713291,0.2268765,0.03522915,0.0003467301,0.002502552,0.0006670428,0.0001490001,0.003012793,0.003990636,0.0009552814,0.01291626,0.0000630169],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9725302,0.01849771,0.0003969109,0.001428043,0.0004151854,0.000443675,0.0009969496,0.0001574416,0.005133771],"genre_scores_gemma":[0.9849985,0.007940026,0.0007952814,0.001003165,0.0002173177,0.0003588531,0.001805432,0.00002903807,0.002852263],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002307214,"threshold_uncertainty_score":0.007718384,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08267231040353823,"score_gpt":0.4386455469096126,"score_spread":0.3559732365060744,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}